BRIEF published on 02/02/2026 at 15:41, 1 month 23 days ago CHEPLAPHARM's Successful €950m Bond Issuance Refinancing Bond Issuance Financial Strategy Investor Demand CHEPLAPHARM
PRESS RELEASE published on 02/02/2026 at 15:36, 1 month 23 days ago Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed CHEPLAPHARM successfully refinances with new 6.750% bond oversubscribed multiple times, enhancing financial flexibility and maturity profile Refinancing Oversubscribed Financial Flexibility CHEPLAPHARM 6.750% Bond
BRIEF published on 08/27/2025 at 13:34, 6 months 29 days ago CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
PRESS RELEASE published on 08/27/2025 at 13:29, 6 months 29 days ago CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRIEF published on 06/26/2025 at 10:36, 8 months 29 days ago CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
PRESS RELEASE published on 06/26/2025 at 10:31, 8 months 29 days ago High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRIEF published on 06/02/2025 at 10:34, 9 months 23 days ago Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
PRESS RELEASE published on 06/02/2025 at 10:29, 9 months 23 days ago Sandra Schröder joins CHEPLAPHARM’S Management Team as VP Scientific Sandra Schröder appointed as VP Scientific at CHEPLAPHARM, responsible for scientific areas globally. Brings 25 years of experience from F. Hoffmann-La Roche AG Pharmaceutical Industry Management CHEPLAPHARM Sandra Schröder VP Scientific
BRIEF published on 01/02/2025 at 09:19, 1 year 2 months ago CHEPLAPHARM Appoints Tamás Szóga as VP Commercial Management Expansion CHEPLAPHARM Tamás Szóga VP Commercial Pharmaceutical Strategy
PRESS RELEASE published on 01/02/2025 at 09:14, 1 year 2 months ago CHEPLAPHARM expands Management with Tamás Szóga as VP Commercial CHEPLAPHARM expands management team by appointing Tamás Szóga as VP Commercial, responsible for strategic planning and development of Global Sales division Global Sales Strategic Planning CHEPLAPHARM Tamás Szóga VP Commercial
Published on 03/26/2026 at 04:55, 2 hours 18 minutes ago Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 00:40, 6 hours 33 minutes ago Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 6 hours 43 minutes ago Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 11 hours 58 minutes ago Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 17 hours 43 minutes ago Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/26/2026 at 07:07, 5 minutes ago Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
Published on 03/26/2026 at 07:05, 8 minutes ago Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children
Published on 03/26/2026 at 07:05, 8 minutes ago EDAG Group: Market uncertainty and delayed awarding of projects shape FY 2025 – Strategic measures accelerated to restore sustainable growth and competitiveness
Published on 03/26/2026 at 07:00, 13 minutes ago WashTec AG: New record revenue of €498.6m with further increase in EBIT margin to 9.8% - at con-stant exchange rates revenue exceeds €500m for the first time
Published on 03/25/2026 at 18:31, 12 hours 42 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 13 hours 28 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
